The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

A dad who thought he had a UTI was diagnosed with stage four bladder cancer and given 24 months to live. Dad-of-two Chris ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...